



全部

图片

新闻

视频

购物

更多

设置

工具

获得 9 条结果 (用时 0.57 秒)

Google 学术 : Treating NAFLD with antidiabetic drugs: are GLP-1 agonists the end of the struggle?

Update on obesity pharmacotherapy - Bray - 被引用次数 : 75

... of lifestyle management and the use of drugs - Standl - 被引用次数 : 5

Advances in the science, treatment, and prevention of ... - Cefalu - 被引用次数 : 64

Novel antidiabetic medications for non-alcoholic fatty liver disease ...

<https://www.ncbi.nlm.nih.gov/pubmed/28019064> - 翻译此页

作者 : Y Sumida - 2017 - 被引用次数 : 7 - 相关文章

1. Hepatol Res. 2017 Mar;47(4):266-280. doi: 10.1111/hepr.12856. Epub 2017 Feb 13. Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 ... such as glucagon-like peptide 1 receptor agonists, dipeptidyl peptidase 4 ... agents and future perspectives on the treatment of NAFLD/NASH with T2DM.

缺少字词 : end struggle

Treatment of patients with type 2 diabetes and non-alcoholic fatty liver ...

<https://www.ncbi.nlm.nih.gov/pubmed/27101131> - 翻译此页

作者 : K Cusi - 2016 - 被引用次数 : 47 - 相关文章

2016年4月21日 - (1)Division of Endocrinology, Diabetes and Metabolism, University ... drugs under development for the treatment of NAFLD/NASH in type 2 diabetes ... Recent promising results with glucagon-like peptide 1 receptor agonists have opened ... Humans; Hypoglycemic Agents/therapeutic use; Insulin Resistance ...

缺少字词 : end struggle

Glucagon like peptide-1 receptor agonists for the management of ...

Name of Journal: *World Journal of Hepatology*

Manuscript NO: 41170

Manuscript Type: EDITORIAL

Treating NASH with antidiabetic drugs: are GLP-1 agonists the end of the struggle?

Maria Kalogirou, Emmanouil Sinakos

Abstract

Nonalcoholic fatty liver disease (NAFLD) is highly associated with insulin resistance, type 2 diabetes mellitus and metabolic syndrome, often characterized as the hepatic component of metabolic syndrome. Despite its high prevalence, no pharmacological treatment has been established, yet. There is growing evidence that reduc-

Match Overview

1	Internet 35 words crawled on 30-Mar-2017 www.wjgnet.com	2%
2	Internet 22 words crawled on 14-May-2016 www.chbnavigator.com	1%
3	Internet 19 words crawled on 20-Jan-2018 www.thieme-connect.com	1%
4	Internet 15 words crawled on 09-Jun-2017 www.clinicaltrials.gov	1%
5	Internet 15 words crawled on 19-Feb-2017 www.jove.com	1%

找到约 8 条结果 (用时 0.57 秒)

Novel antidiabetic medications for non-alcoholic fatty liver disease ...

<https://www.ncbi.nlm.nih.gov/pubmed/28019064> - 翻译此页

作者 : Y Sumida - 2017 - 被引用次数 : 8 - 相关文章

1. Hepatol Res. 2017 Mar;47(4):266-280. doi: 10.1111/hepr.12856. Epub 2017 Feb 13. Novel **antidiabetic medications** for **non-alcoholic fatty liver disease** with type 2 ... such as **glucagon-like peptide 1 receptor agonists**, dipeptidyl peptidase 4 ... agents and future perspectives on the **treatment** of **NAFLD/NASH** with T2DM.

缺少字词 : end struggle

Glucagon like peptide-1 receptor agonists for the management of ...

<https://www.ncbi.nlm.nih.gov/pubmed/28918389> - 翻译此页

作者 : G Dhir - 2017 - 被引用次数 : 3 - 相关文章

2017年9月15日 - **Glucagon like peptide-1 receptor agonists** for the management of obesity and ... In **non-alcoholic fatty liver disease (NAFLD)**, liver fat (triglyceride) ... Although pioglitazone is emerging as the **treatment** of choice for NASH in ...

缺少字词 : antidiabetic drugs end struggle

Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic ...

<https://www.ncbi.nlm.nih.gov/pubmed/25356042> - 翻译此页

作者 : XC Wang - 2014 - 被引用次数 : 35 - 相关文章

2014年10月28日 - Glucagon-like peptide1 (GLP-1) is secreted from Langerhans cells in response to ... **agonists** (GLP-1RAs) are a new class of incretin-based **anti-diabetic drugs**. ... has suggested potential applications of these drugs in the **treatment** of ... the prevalence of **non-alcoholic fatty liver disease (NAFLD)** in China is ...

缺少字词 : end struggle

[全部](#)[图片](#)[新闻](#)[视频](#)[购物](#)[更多](#)[设置](#)[工具](#)

找到约 8 条结果 (用时 0.51 秒)

Novel antidiabetic medications for non-alcoholic fatty liver disease ...

<https://www.ncbi.nlm.nih.gov/pubmed/28019064> - 翻译此页

作者: Y Sumida - 2017 - 被引用次数: 8 - 相关文章

1. Hepatol Res. 2017 Mar;47(4):266-280. doi: 10.1111/hepr.12856. Epub 2017 Feb 13. Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 ... Non-alcoholic steatohepatitis (NASH), a severe form of NAFLD, can lead to ... such as glucagon-like peptide 1 receptor agonists, dipeptidyl peptidase 4 ...

缺少字词: end struggle

Glucagon like peptide-1 receptor agonists for the management of ...

<https://www.ncbi.nlm.nih.gov/pubmed/28918389> - 翻译此页

作者: G Dhir - 2017 - 被引用次数: 4 - 相关文章

2017年9月15日 - Glucagon like peptide-1 receptor agonists for the management of obesity ... In non-alcoholic fatty liver disease (NAFLD), liver fat (triglyceride) ... In this review, we will briefly summarize the status of GLP-1RA for the treatment of ...

缺少字词: antidiabetic drugs end struggle

GLP-1 receptor agonists: effects on the progression of non-alcoholic ...

<https://www.ncbi.nlm.nih.gov/pubmed/25066109> ▼ 翻译此页

作者: J Liu - 2015 - 被引用次数: 18 - 相关文章

2014年9月14日 - Non-alcoholic fatty liver disease (NAFLD) is one of the most ... (GLP-1), a receptor agonist is a new drug approved for treating type 2 diabetes.

缺少字词: antidiabetic end struggle

New Medications for the Treatment of Diabetes | Diabetes Technology ...

<https://www.liebertpub.com/doi/full/10.1089/dia.2015.1514> ▼ 翻译此页

作者: SK Garg - 2015

A primary end-point event occurred in 613 patients in the saxagliptin group and in 609 ... Gliptins are new oral antidiabetic drugs that increase insulin levels through ... for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus ... GLP1 analogs might provide a new treatment option in patients with ...

Management of Nonalcoholic Fatty Liver Disease in Patients With ...

care.diabetesjournals.org/content/40/3/419 ▼ 翻译此页

作者: F Bril - 2017 - 被引用次数: 46 - 相关文章

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver condition ... This review will